Want to reduce Time to Clinic for your Viral Vector?
Sponsored by: Sartorius Stedim Biotech
- Viral Vectors
- Downstream Process Development
Date: 6 December
Days to go: 52
Time: 3PM London/10AM New York
High-Throughput Solutions for Downstream Process Development
Viral vectors have become one of the most rapidly evolving and promising fields in vaccinology and regenerative medicine. The development of the Downstream Process is challenging because each vector has its own properties. There is not one-fit-all solution. How then should process development scientists approach the development of a viral vector purification process, knowing that each process is unique?
This webinar will give you an overview of the Sartorius approach to accelerate the development of Downstream Processing, combining our well proven technologies – such as membrane chromatography and tangential flow filtration – with state-of-the art automated systems and Design of Experiment Software.
The presentation will include an introduction to the first ambr® system applied to Downstream Processing. ambr® crossflow is a benchtop system optimised for ultrafiltration and diafiltration applications, capable of performing up to 16 trials in parallel.
Please register to reserve your spot for this exciting webinar and we look forward to welcoming you to our presentation.
Vaccine Platform Marketing Manager
Amélie Boulais started her collaboration with Sartorius in 2008 as Application Specialist for the Purification Technologies division, responsible for Southern Europe.
In 2012, she became membrane chromatography and virus clearance project manager, covering Europe. She was focusing on polishing and virus clearance. She became part of the Process Development Consultant team in 2015, supporting and advising actors of the biopharma industry in their development from Upstream to final filling operations.
She joined the Bioprocess Platform team in 2016, taking over the responsibility of vaccine applications. She is analysing the trends of the vaccine industry in order to develop fully scalable platforms with the required associated process development support and related services for vaccine applications. Amélie graduated from ENSTBB (Biotechnology Engineering Institute of Bordeaux, France) and holds a Biotechnology Engineer degree.
Key Learning Objectives
- Developing viral vector downstream processes
- Latest solutions to speed-up process development
- High Throughput Process Development of ultrafiltration / diafiltration with ambr®
- Discovering a platform approach for viral vector manufacturing
- Process Development Scientists
- Process Development Managers
- Process Engineers
- Engineering Directors